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Available online 1 July 2016Background: Pulmonary congestion is a common presentation of acute decompensated heart failure (ADHF). The
ability to quantify increased pulmonary parenchymalwater content in chest computed tomography (CCT) iswell
known. However, availability and radiation limitationsmake it unsuitable for serial assessment of lung ﬂuid con-
tent. The ReDS™ technology allows quantiﬁcation of lung ﬂuid content.
Objective: The objective of this work was to validate the ability of the ReDS™ technology to quantify total lung
ﬂuid when compared with CCT in ADHF and non-ADHF patients.
Methods: Following CCT, ReDSmeasurementswere obtained from consented subjects. ReDSmeasurementswere
then compared to the CCT using lung density analysis software. CCT results were converted from Hounsﬁeld
Units to percentage units, allowing comparison with the ReDS readings. The analyses, performed on 16 ADHF
and 15 non-ADHF patients, were conducted by an independent observer blinded to ReDS outcomes.
Results: The ﬂuid content averages and standard deviations for the non-ADHF group were 28.7 ± 5.9% and
27.3 ± 6.6% and for the ADHF patients 40.7 ± 8.8% and 39.8 ± 6.8% (CCT and ReDS respectively). Intraclass
correlation was found to be 0.90, 95% CI [0.8–0.95]. Regression analysis yielded a slope of 0.94 (95% conﬁdence
interval [0.77–1.12]) and intercept 3.10 (95% conﬁdence interval of [−3.02–9.21]). The absolutemean difference
between the quantiﬁcation of the two methods was 3.75 [%] with SD of 2.22 [%].
Conclusion: Current ﬁndings show high correlation between the ReDS noninvasive system and CCT in both ADHF
and non-ADHF patients. Remote patient monitoring using ReDS™ based systemmay help in themanagement of
patients with heart failure.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Fluid management
Heart failure
Diuretics
Telemonitoringsponsored by Sensible Medical
sh-Abboud and Dr. Nizar have
Amir was an SMI consultant at
ant to SMI. Dr. Abbo is an SMI
West 12th Avenue, Room 110P,
braham).
land Ltd. This is an open access articl1. Introduction
Early detection of impending volume overload by sensing increases
in pulmonary artery pressures in patients with heart failure facilitates
intervention such asmodiﬁcation of pharmacological therapy or behav-
ior (e.g., diet, mediation compliance) to avoid rehospitalizations. This
was demonstrated in the COMPASS-HF [1] and CHAMPION [2] studies.
However, these prior studies relied on invasive, permanently implanted
pressure sensors. In addition, previous studies employing chest
computed tomography (CCT) to quantify lung ﬂuid content in heart
failure patients spanning a wide range of symptoms (including patientse under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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occurred when lung ﬂuid content increases above 50% of normal values
[3–7]. A valid, noninvasive approach that provides equivalent informa-
tion would provide many advantages.
We previously described the potential of a novel noninvasive elec-
tromagnetic energy-based technology [8] (Remote Dielectric Sensing,
ReDS™) intended to quantify changes in lung ﬂuid content. Brieﬂy,
ReDS™ technology (Sensible Medical Innovations Ltd., Kfar Neter,
Israel) measures the dielectric properties of tissues. Low power electro-
magnetic signals are emitted across the thorax through the lung and the
characteristics of the signals received after passing through the tissue
are related to their dielectric properties which, in turn, are mostly
determined by the lung's ﬂuid content [8]. This contrasts with
bio-impedance-based devices which apply low frequency currents to
measure electrical resistance between body surface electrodes which
is affected by many factors in addition to lung ﬂuid content
(e.g., electrode placement, body habitus, fat content, skin moisture) [9].
The purpose of the current study was to test the accuracy of the
ReDS™ system by comparing its measurement of lung ﬂuid content to
thatmeasured by chest computed tomography (CCT)which is currently
the most accurate method for quantifying lung ﬂuid content in vivo
[10–12]. Patients with and without acute decompensated heart failure
(ADHF) were recruited to ensure lung ﬂuid contents spanning the
range expected in clinical use.
2. Methods
2.1. Patients
A total of 36 patients were included from two different clinics. 19 patients recruited at
Carmel Medical Center did not have any evidence of heart failure. 17 patients with ADHF
were recruited at RambamMedical Center. The ADHF patients underwent CCT as part of
the study protocol during their ADHF-related hospitalization, with the presence of ADHF
being the only inclusion criterion. The inclusion criterion for non-ADHF patients was
that they had a clinical indication for CCT as an elective procedure. Exclusion criteria for
the non-ADHF patients were clinically unstable patients, known pregnancy, recent cardio-
thoracic surgery, recent chest trauma or age b 18 years.
The respective protocols were approved by the IRB committees of RambamMedical
Center and Lady Davis Carmel Medical Center, Haifa, Israel. All the participating patients
signed written informed consent prior to participation.
Each patient underwent ReDS and CCT measurements by a trained technical staff to
quantify lung ﬂuid content according to a standardized protocol. During the measure-
ments, a spirometer (WaveFront™, Thor) was used for registration of breathing pattern
to enable comparison between the two modalities at the same phase of respiration.
2.2. Chest CT measurements
The CCT test was performed according to routine practice by an experienced hospital
technician. Patients were instructed to hold their breath as required by the standard CCT
protocol. In order to record the air volume at the speciﬁc time when respiration was
paused, the patient was asked to breathe through a spirometer (WaveFront™, Thor®)
during scanning. This procedure allows for correction of lung air volume for appropriate
comparison between the corresponding CCT and ReDS™measurements.
After redacting patient identity, each CCT scan was saved to CD and analyzed subse-
quently by an independent blinded operator at a Siemens® workstation using lung anal-
ysis software (syngo.CT Pulmo 3D, Siemens®) which provides semi-automatic tools toFig. 1.Wearable veanalyze mean lung density (MLD). Mean lung density is deﬁned as the average attenua-
tion value of all voxels belonging to the lung and is measured in Hounsﬁeld Units [HU].
MLD was then converted to ﬂuid content (FC) in percentage units according to the
equation: FC [%] = (MLD + 1000) / 10, which is based on the Hounsﬁeld Units scale in
which 0 HU is the value for water and−1000 HU is the value for air. The CCT FC values
were then adjusted for the average lung volume obtained by spirometry to compensate
for variations in lung air volumes during breath holds. The formula and other aspects of
the protocols and analyseswere previously validated and used by others [13–17]. This ap-
proach allows for comparison of ReDS and CCT readings in the same units of measure
(i.e., percentage of lung volume consisting of water).
2.3. ReDS™
2.3.1. Technology
ReDS™ technology was originally developed by the military as a “see through wall”
technology to identify survivors in rubble. The technology is based on a miniature radar
system that employs low-power electromagnetic signals emitted into the body. The tech-
nology, implemented in awearable vest, does not require contactwith the skin and can be
worn on top of clothing (Fig. 1).
Two sensors embedded in awearable garment are attached to the body: one anterior-
ly on the chest and the other posteriorly on the patients' back. Each sensor is a small round
device capable of transmitting and receiving the focused EM wave beam transferred
through the pulmonary tissue. The analyzed signal reﬂects the dielectric properties of
the section of the lung between the sensors. The dielectric coefﬁcient of a material is rep-
resented by a frequency-dependent complex number describing its interaction with elec-
tromagnetic energy including the degrees of absorption, reﬂection and transmission of the
energy. Since water has a very high dielectric coefﬁcient, dielectric coefﬁcients of tissues
are determined predominantly by their ﬂuid content [18,19]. For example, healthy fat tis-
sue, which has low ﬂuid content, is characterized by a relatively low dielectric coefﬁcient,
while healthymuscle tissue that is relatively rich in water is characterized by a higher di-
electric coefﬁcient. In addition, air has the lowest dielectric coefﬁcient [18,19].
The dielectric coefﬁcient of pulmonary tissue is determined by the dielectric coefﬁ-
cients of each of its components (e.g., blood, lung parenchyma, and air) and their relative
concentrations. In the end, it is considered that the lung is primarily composed of air and
water, componentswith widely different dielectric coefﬁcients. Accordingly, the dielectric
coefﬁcient of the intact lung is very sensitive to the ratio between the volumes of air and
water and thus, this number is a direct indicator of ﬂuid concentration.
Thehealthyhuman lung (for anaverage 70kgperson) contains 450 to 500ml of blood
[20]. The extravascular compartment normally contains another 250 to 700 ml of ﬂuid
[21]. Since the normal total lung air volume at functional residual capacity is 1.8 to 2.2 l
[22] with a tidal volume of 500 ml, it can be estimated that the intrathoracic ﬂuid content
ranges between 20 and 35% of the total volume. This range has been conﬁrmed by lung
density measurements performed by different quantitative imaging technologies (i.e.
computed tomography, nuclear magnetic resonance imaging and positron emission to-
mography) [23–26].
2.4. Measurements
The ReDS™ measurements were performed by trained operators following the CT
scanwith patient lying in a hospital bed. Each patient's primary carephysicianwas blinded
to the ReDS™ data. The raw signals were stored on a computer and were analyzed using
an algorithm that provided the pulmonary ﬂuid content in units of percent (%). The oper-
ators and the observer who performed and analyzed the CT scans were also blinded to
ReDS readings.
2.5. Statistical analyses
For descriptive statistics, continuous variables are presented asmeans± standard de-
viation (SD) as well as minimum–maximum values. For categorical variables, the number
and percent of non-missing values for each categorywithin a parameter are calculated. For
selected parameters, 95% conﬁdence intervals of the mean are presented. T-test was used
for comparing the ﬂuid content [%]means of the two groups (ADHF and non-ADHF) basedst and console.
Table 1
Patients' characteristics.
Baseline characteristic
Parameter Mean ± SD
[Min–Max]
ADHF Non-ADHF
N 31 15 16
Age [year] 71.7 ± 11.2 [54–89] 73.8 ± 10.8 [56–89] 69.4 ± 11.6 [54–89]
Male n (%) 19 (61%) 10 (62.5%) 9 (60%)
Female n (%) 12 (39%) 6 (37.5%) 6 (40%)
Weight [kg] 77.3 ± 14.7 [57–113] 75.7 ± 15.7 [57–105] 78.9 ± 14.1
[60–113]
Height
[meter]
1.68 ± 0.09
[1.55–1.86]
1.68 ± 0.08
[1.55–1.78]
1.69 ± 0.1
[1.55–1.86]
BMI [kg/m2] 27.1 ± 4.8
[19.5–39.8]
26.7 ± 5.1
[19.6–39.8]
27.5 ± 4.7
[21.0–35.4]
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in the ADHF group were calculated together with 95% conﬁdence intervals and p-values.
The correlation between the ReDS and CCT lung ﬂuid content was calculated using
intra-class correlation (ICC) type (1, 3) with 95% conﬁdence intervals and p-values.
Bland–Altman analysis was used to compare the difference between the two lung
ﬂuid measurement methods (CT and ReDS).
Statistical signiﬁcance is declaredwhen the p value is found to be less than or equal to
0.05. All descriptive and inferential statistical analyses were performed using SAS statisti-
cal software, version 9.4.Fig. 3. ReDS™ vs. CT— comparison of lung ﬂuid level quantiﬁcation (N= 31).3. Results
The ﬁnal analysis included data from 31 of the 36 patients enrolled;
low quality spirometry data acquisition prevented CCT and ReDS data
comparison in 5 patients. Of the 31 patients in the ﬁnal analysis, 16 pa-
tients were in the ADHF group and 15 patients were in the non-ADHF
group. Patient characteristics are summarized in Table 1. The ADHF pa-
tients averaged 73.8 years of age weighing 75.7 kg with a BMI of 26.7;
62.5% were male. The characteristics of the non-ADHF group were sim-
ilar with an average age of 69.4 years, a weight of 78.9 kg and a BMI of
27.5; 60.0% were male.
As noted above, CCT was performed in all the ADHF patients as part
of the study protocol. None of those patients had parenchymal
pulmonary pathologies; one of these patients had COPD. For non-
ADHF patients, CCT was performed as part of their routine medical
work-up. In 12 patients, this was for evaluation of pulmonary diseases
(such as cancer, pneumonia, atelectasis, suspected PE), of which 3
patients had COPD. For the remaining 3 patients, the CCT was for
evaluation of diseases of the mediastinum or aorta. Fig. 2a shows the
CT of an ADHF patient; his ReDS reading was 46%. In comparison, Fig.
2b shows the CT of an ambulatory non-heart failure patient; his ReDS
reading was 23%.
The percent ﬂuid content in the lungs ranged between 17% and 60%
by CCT and between 19% and 55% by ReDS. With data from all patientsFig. 2. (a) CT of ADHF patient with pulmonary edema (b) Cpooled, lung ﬂuid content averaged 34.9 ± 9.6% by CCT and 33.8 ±
9.2% by ReDS.
CCT and ReDS™ measurements of pulmonary ﬂuid content were
compared in each patient as summarized in Fig. 3. The intraclass
correlation, which provides a mean to quantify the similarity between
absolute values, was found to be 0.90 [95% CI: 0.80–0.95]. Regression
analysis applied to these data yielded a slope of 0.94 (95% conﬁdence
interval [0.77, 1.12]) and intercept 3.15 (95% conﬁdence interval of
[−2.97, 9.27]).
The Bland and Altman analysis (Fig. 4) illustrates the agreement
between the two modalities by plotting the difference between the
ReDS™ and CT pulmonary ﬂuid measurements as a function of the
average of the two measurements for each patient. As the plot shows,
the points are scattered roughly evenly across the entire 15–60% range
of ﬂuid content values, which indicates that ReDS and CCT have compa-
rable accuracy at low and high values of lung ﬂuid content. The absolute
difference in measurements between the two methods (i.e., the sum of
all |CT-ReDS™| values) was 3.75% with a standard deviation of 2.22%.
Both CCT and ReDS™ yielded higher values for pulmonary ﬂuid con-
tents in ADHF patients as compared to non-ADHF patients (Fig. 5,
p b 0.001 for each comparison). The mean CT value for the ADHF
group was 40.7% with 95% CL of [36.0%–45.4%] compared to 28.7%
with 95% CI of [25.4%–32.0%] for the non-ADHF group. The ReDS valuesT of ambulatory non-heart failure patient (dry lungs).
Fig. 5. Pulmonary ﬂuid content: CCT and ReDS comparison between ADHF and non-ADHF group.
Fig. 4. Bland–Altman analysis comparing ReDS™ and CT pulmonary ﬂuid quantiﬁcations.
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pared to a mean value of 27.3% with 95% CL of [23.6%–31.0%] for the
non-ADHF group.
4. Discussion
Dyspnea due to lung congestion is one of the leadingmanifestations
of ADHF [27]. Early detection of systemic ﬂuid overload and/or pulmo-
nary congestion is the cornerstone for the prevention of acute HF de-
compensations, especially in high-risk patients. Accordingly, several
strategies have been tested for early detection of meaningful increases
in lung ﬂuid content prior to full blown exacerbations requiring
hospitalization. Remote telemonitoring using weight or detecting
changes in bio-impedance, including internal implanted devices and
wireless pressure sensors have been investigated with variable success
[28–31]. The use of weight and symptoms as well as intrathoracic
bio-impedance in randomized controlled studies had failed to reduce
hospitalizations [32–34].
However, it was demonstrated in the CHAMPION study [3] that use
of invasive pulmonary artery pressure monitoring successfully reduced
the rate of hospitalizations by 33% over a mean follow-up time of
15 months. Most recently, during the open access phase of the study,
therewas a 48% reduction in the rate of readmissions over an additional
mean 13 months follow-up period among the control group patients
compared to their hospitalization rate during the randomized phase
during which therapy was not guided by pulmonary artery pressure
readings [35].
The ReDS™ system, which sends a focused electromagnetic beam
through the chest cavity enabling direct measurement of the lung
ﬂuid content, is portable, non-invasive and easy to use and requires
minimal patient collaboration. In our previous studies, we showed in
an animal model that both chest CT and ReDS™ technology were sensi-
tive in detecting changes in lung ﬂuid content and demonstrated a high
interclass and Pearson correlation coefﬁcients of 0.95 [8] (and unpub-
lished data). Moreover, we showed the fast response of ReDS™ to in-
duced changes in pulmonary ﬂuid volume status. In the clinical
studies, we also demonstrated a strong correlation between ReDS™
measurements and ﬂuid status during diuresis measured throughout
the hospital admission of the ADHF patients [8]. The results of the
present study provide direct validation of the accuracy of ReDS when
compared to CCT, the current gold standard for measuring lung ﬂuid
content. This contrasts with bio-impedance-based measurements
which are affected by many factors other than lung ﬂuid content. Ac-
cordingly, ReDS may provide information that is clinically comparable
to hemodynamic measurements, but is noninvasive.
5. Limitations
The present study focused on validating ReDS to measure lung ﬂuid
content. Direct comparison of ReDS to pulmonary pressures has not yet
been performed. Nevertheless, initial results indicate that detection of
changes in lung ﬂuid content by ReDS measurements can be used to
guide medical therapy and reduce HF hospitalizations in patients at
high risk for readmission (ReDS-HF) [36,37]. Further validation of this
ﬁnding is being obtained in a prospective, randomized study
(SMILE™, NCT02448342).
6. Summary and conclusions
In summary, we have demonstrated that ﬂuid content quantiﬁed by
the ReDS™ system is highly correlated to CCT in quantifying pulmonary
ﬂuid content over a wide range of ﬂuid content levels spanning the ap-
plicable clinical range. The ReDS™ system offers a reliable, non-invasive
and portable technology for detection of even mild lung ﬂuid content
changes at the pre-symptomatic state, and may potentially assist mon-
itoring patientswith ﬂuidmanagement problems (includingHF) duringhospital admission and/or in ambulatory settings. Initial experience
with ReDS™ guided-remote patient monitoring has been presented
recently [36,37]. A larger randomized study is currently recruiting
patients and will test the hypothesis that ReDS-based lung ﬂuid status
monitoring reduces the rate of heart failure readmissions (SMILE™,
NCT02448342).
Clinical perspective
The ReDS™ technology described in this paper provides an absolute
measure of lung ﬂuid content that makes the measure immediately ac-
tionable. A reliable, non-invasive and portable technology for detection
of lung ﬂuid content changes at the pre-symptomatic state, can assist
monitoring patients with different ﬂuid management problems such
as trauma, heart failure, and renal failure. Monitoring and management
by ReDS technology is applicable either during admission and/or in the
ambulatory setting, and may potentially help reduce readmissions of
these patients, a signiﬁcant clinical challenge especially in the heart
failure patients' population.
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